PT  - JOURNAL ARTICLE
AU  - L Atmowihardjo
AU  - J Schippers
AU  - E Duijvelaar
AU  - I Bartelink
AU  - P Bet
AU  - N Van Rein
AU  - K Purdy
AU  - D Cavalla
AU  - A Flamarion
AU  - A Mcelroy
AU  - S Fritchley
AU  - M Koopmans
AU  - H J Bogaard
AU  - L Heunks
AU  - N Juffermans
AU  - M Schultz
AU  - P R Tuinman
AU  - H Endeman
AU  - P Van Velzen
AU  - L Bos
AU  - J Aman
TI  - The efficacy and safety of intravenous imatinib in invasively ventilated patients with COVID-19 related acute respiratory distress syndrome (InventCOVID): a multicentre, randomised, double-blinded, placebo-controlled, phase II clinical study
AID  - 10.1183/13993003.congress-2022.4582
DP  - 2022 Sep 04
TA  - European Respiratory Journal
PG  - 4582
VI  - 60
IP  - suppl 66
4099  - http://erj.ersjournals.com/content/60/suppl_66/4582.short
4100  - http://erj.ersjournals.com/content/60/suppl_66/4582.full
SO  - Eur Respir J2022 Sep 04; 60
AB  - Background: A central hallmark of ARDS is hypoxemic respiratory failure due to increased pulmonary capillary leakage. The kinase inhibitor imatinib was shown to reverse vascular leak. This study aimed to investigate the effect of intravenous imatinib on pulmonary edema in patients with COVID-19 ARDS.Methods: This multicentre, randomised, double-blind, placebo-controlled clinical trial (ClinicalTrial.gov identifier NCT04794088) included adult patients admitted to the ICU with moderate or severe COVID-19 ARDS. Patients were randomised 1:1 to receive 200mg intravenous imatinib or placebo twice daily for seven days or until ICU discharge. The change in extravascular lung water index between day 1 and day 4, measured using a PiCCO catheter, was chosen as the primary endpoint. Secondary outcomes included the PaO2/FiO2 ratio, number of ventilator free days, length of ICU admission and 28-day mortality rate. Study drug safety was assessed by daily screening of the patient records for adverse and serious adverse event occurrence and by performing ECGs and targeted clinical laboratory tests to monitor renal, liver and cardiac function.Results: Between March 2021 and 2022, 67 predominantly male (58%) patients with a mean age of 63±10 years were randomized to receive imatinib or placebo. No adverse events were considered to be related to study drug administration. At the moment of the abstract submission, data cleaning is still ongoing.Conclusion: Thus far, intravenous imatinib administration seems safe and feasible in patients with COVID-19 related ARDS.FootnotesCite this article as Eur Respir J 2022; 60: Suppl. 66, 4582.This article was presented at the 2022 ERS International Congress, in session “-”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).